Literature DB >> 14745558

Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549).

Michael Jung1, Steven Grunberg, Cynthia Timblin, Sylke Buder-Hoffman, Pamela Vacek, Douglas J Taatjes, Brooke T Mossman.   

Abstract

Concurrent administration of paclitaxel and vinorelbine results in cytotoxicity in vivo and in vitro in a number of tumor cell lines, yet the mechanisms of enhanced cell killing are undefined. In studies here, we show that low concentrations (1 nM) of paclitaxel and vinorelbine in combination result in enhanced cell killing by apoptosis ( P<0.05) in the human lung adenocarcinoma cell line, A-549. In contrast, necrotic cell death and formation of multinucleated cells, which were significantly increased by paclitaxel ( P<0.05) alone, but not vinorelbine, were not increased synergistically by both drugs. Paclitaxel also caused microtubular disruption which was not observed with vinorelbine. These data provide further rationale for the combined use of paclitaxel and vinorelbine in clinical trials, and suggest that the cooperative effects of drugs on apoptosis are not mediated through similar disruptional effects on microtubules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745558     DOI: 10.1007/s00418-004-0618-8

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  22 in total

Review 1.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.

Authors:  C Dumontet; B I Sikic
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

2.  Microtubule antagonists activate programmed cell death (apoptosis) in cultured rat hepatocytes.

Authors:  K Tsukidate; K Yamamoto; J W Snyder; J L Farber
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

3.  Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C.

Authors:  K C Das; C W White
Journal:  J Biol Chem       Date:  1997-06-06       Impact factor: 5.157

4.  Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways.

Authors:  T H Wang; H S Wang; H Ichijo; P Giannakakou; J S Foster; T Fojo; J Wimalasena
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

5.  In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines.

Authors:  A Photiou; P Shah; L K Leong; J Moss; S Retsas
Journal:  Eur J Cancer       Date:  1997-03       Impact factor: 9.162

6.  Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.

Authors:  Amalia Gómez-Bernal; Juan Jesús Cruz; Andrés García-Palomo; Alberto Arizcun; Eduardo Pujol; Pilar Diz; Germán Martín; Emilio Fonseca; Pedro Sánchez; César Rodríguez; Elvira del Barco; Yolanda López
Journal:  Am J Clin Oncol       Date:  2003-04       Impact factor: 2.339

7.  Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis.

Authors:  O S Frankfurt; J A Robb; E V Sugarbaker; L Villa
Journal:  Exp Cell Res       Date:  1996-08-01       Impact factor: 3.905

8.  First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.

Authors:  C Kourousis; N Androulakis; S Kakolyris; J Souglakos; G Maltezakis; G Metaxaris; G Chalkiadakis; G Samonis; J Vlachonikolis; V Georgoulias
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

9.  Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.

Authors:  José Miguel Sánchez; Carme Balañá; Albert Font; José Javier Sánchez; José Luis Manzano; Mónica Guillot; Mireia Margelí; Martin Richardet; Rafael Rosell
Journal:  Lung Cancer       Date:  2002-12       Impact factor: 5.705

10.  Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer.

Authors:  A Y Chang; G C Garrow
Journal:  Semin Oncol       Date:  1995-04       Impact factor: 4.929

View more
  6 in total

Review 1.  Recent progress in histochemistry and cell biology: the state of the art 2005.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2005-11-11       Impact factor: 4.304

2.  Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function.

Authors:  Dan L Sackett; Laurent Ozbun; Enrique Zudaire; Lisa Wessner; John M Chirgwin; Frank Cuttitta; Alfredo Martínez
Journal:  Endocrinology       Date:  2008-03-06       Impact factor: 4.736

3.  Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells.

Authors:  Qiong Zhou; Yuan Su; Ming Bai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-02

Review 4.  News and views in Histochemistry and Cell Biology.

Authors:  Esther Asan; Detlev Drenckhahn
Journal:  Histochem Cell Biol       Date:  2004-12-22       Impact factor: 2.531

Review 5.  Nanomechanics in Monitoring the Effectiveness of Drugs Targeting the Cancer Cell Cytoskeleton.

Authors:  Andrzej Kubiak; Tomasz Zieliński; Joanna Pabijan; Małgorzata Lekka
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

Review 6.  Morphological and cytochemical determination of cell death by apoptosis.

Authors:  Douglas J Taatjes; Burton E Sobel; Ralph C Budd
Journal:  Histochem Cell Biol       Date:  2007-11-14       Impact factor: 4.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.